Instilling Robust QbD, Optimized Process Development & Control Strategy for Next Gen Oligos & Peptides to Ensure Scalability, Regulatory Compliance & Affordability
The inaugural Oligos & Peptides Formulation & Process Development Summit is the industry’s first forum bringing together experts addressing challenges and seeking solutions to expedite drug discovery!
Recently, Biogen’s announcement of $60m upfront investment on a new antisense candidate from Ionis, and Janssen’s strategic collaboration with i2O Therapeutics for macromolecules, demonstrated drug developers’ interest in next generation complex oligonucleotides and peptides have reached unprecedented level.
With the emergence of liquid phase synthesis technologies, improved bioavailability, and delivery approaches of oligos and peptides, drug developers realize the therapeutic potential of this 2nd generation of macromolecules can go beyond rare diseases with commercial viability.
Join 60+ of your peers and be part of this growing community. Featuring exclusive presentations, hands-on workshops, hours of networking from 18+ oligo and peptide thought-leaders, this summit will share exclusive insights on:
QbD for winning formula to optimize process development for complex oligos & peptides’
Synthesis strategies to improve stability of DS and DP
Updates on regulatory and CMC compliance
Seamless scale-up and tech transfer in collaboration with your CDMO partners
World-Class Speaker Faculty
Director of Engineering
Eli Lilly & Company
Senior Director, Medicine Chemistry
Senior Principal Scientist, New Modalities
What do Our Customers Have to Say?
"’This summit was very helpful for learning and working. I would like to recommend this to my fellow colleagues”
Associate Director, BMS
"The event topics, organization and support staff were excellent”
Associate Director, Advanced Instruments
"The summit is informative and helpful. I enjoyed the presentations and opportunities to network”
VP, Beam Therapeutics
"Excellent opportunity to network with players in the field”
VP, BioNTech AG
"’I enjoyed many of the talks and opportunity to network with CDMOs”
Senior Scientist, Janssen